Effect of Imatinib in Advance Liver Fibrosis Patients
Status:
Active, not recruiting
Trial end date:
2022-09-02
Target enrollment:
Participant gender:
Summary
When a recurrent, long-term injury and inflammation of the liver causes an excessive
accumulation of damaged tissue, a dangerous condition called liver fibrosis develops. Most
chronic liver diseases eventually lead to fibrosis. Activated hepatic stellate cells (aHSC)
play an important role in the development of hepatic fibrosis. Inhibiting the proliferation
of stellate cells and preventing their differentiation and activation is an ideal strategy
for ameliorating hepatic fibrosis. Hence imatinib have been prescribed as a promising drug to
limit the progression of liver fibrosis as a clinical inhibitor of tyrosine kinase which can
affect the two main pathways leading to hepatic stellate cells activation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Research Institute for Gastroenterology and Liver Diseases (RIGLD)